FGFR3 A500T

CI-VAR-00000103Explore in graph →NP_000133.1:p.Ala500ThrNM_000142.5:c.1498G>AClinVar 1680079 CIViC 4049

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
FGFR3 A500T	(oncogenic)	Oncogenic	D	Does Not Support Oncogenicity	2	accepted	EID13092 In a saturation mutagenesis study, all possible single nucleotide substitutions in the FGFR1-4 kinase domain (amino acids 472-807 for FGFR3) were tested. Lentiviral plasmids were infected at MOI < 0.3… (full text at CIViC) PMID 41361008 · Tangermann et al., 2025 · Open in CIViC	civic
Unmapped disease1unmapped disease
FGFR3 A500T	(functional)	Functional	D	Does Not Support Gain Of Function	2	accepted	EID13090 FGFR3 variant A500T was assessed among a panel of 26 FGFR3 kinase domain variants using purified protein in vitro auto-phosphorylation assays (Figure 2A). Compared to wild type, A500T showed only a sm… (full text at CIViC) PMID 26992226 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.